Microbiota Restoration in Recurrent C. difficile and COVID-19

Released On
May 6, 2020

Expires On
September 6, 2020

Media Type
Internet

Completion Time
45 minutes

Specialty
Critical Care, Gastreoenterology, Infectious Disease, Primary Care

Topic(s)
Clostridioides difficile

Scroll to the Bottom of this Information to Begin this Course

This activity is sponsored by the Academy for Continued Healthcare Learning.

This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for gastroenterologists, infectious disease specialists, and other clinicians who care for patients at risk of serious infection.

Program Overview

In this activity, Dr. Paul Feuerstadt and Dr. Sahil Khanna discuss how the global COVID-19 pandemic presents increasing safety measures for patients with recurrent Clostridioides difficile Infection (rDCI) that are candidates for fecal microbiota transplantation (FMT). In this video-based format, our faculty share why clinicians need to be aware of screening and safety protocols, and how to manage rDCI patients during this unprecedented time.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the burden of recurrent C. difficile
  • Review the efficacy and safety of current approaches to using fecal microbiota for transplantation
  • Outline the implications of the COVID-19 pandemic on the treatment of recurrent C. difficile

Faculty

Paul Feuerstadt MD, FACG, AGAF

Paul Feuerstadt MD, FACG, AGAF




Assistant Clinical Professor of Medicine
Yale University School of Medicine
Gastroenterology Center of Connecticut

Sahil Khanna, MBBS, MS

Sahil Khanna, MBBS, MS




Associate Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

The following financial relationships have been provided:

Paul Feuerstadt, MD, FACG, AGAF

  • Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
  • Speakers' Bureau: Merck and Company

Sahil Khanna, MBBS, MS

  • Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc
  • Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC

Instructions for Participation and Credit

This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.